Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Nash, Peter; Coates, Laura C; Fleischmann, Roy; Papp, Kim A; Gomez-Reino, Juan Jesus; Kanik, Keith S; Wang, Cunshan; Wu, Joseph; Menon, Sujatha; Hendrikx, Thijs; Ports, William C

Nash, Peter; Coates, Laura C; Fleischmann, Roy; Papp, Kim A; Gomez-Reino, Juan Jesus; Kanik, Keith S; Wang, Cunshan; Wu, Joseph; Menon, Sujatha; Hendrikx, Thijs; Ports, William C.

Afiliação

Nash P; Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia. drpnash@tpg.com.au.
Coates LC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Fleischmann R; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
Papp KA; Probity Medical Research and K Papp Clinical Research Inc, Waterloo, ON, Canada.
Gomez-Reino JJ; Fundación Ramón Domínguez, Hospital Clinico Universitario, Santiago de Compostela, Spain.
Kanik KS; Pfizer Inc, Groton, CT, USA.
Wang C; Pfizer Inc, Groton, CT, USA.
Wu J; Pfizer Inc, Groton, CT, USA.
Menon S; Pfizer Inc, Groton, CT, USA.
Hendrikx T; Pfizer Inc, Collegeville, PA, USA.
Ports WC; Pfizer Inc, Groton, CT, USA.

Rheumatol Ther ; 5(2): 567-582, 2018 Dec.

Article em En | MEDLINE | ID: mdl-30414064

Palavras-chave

Janus kinase inhibitor; Psoriatic arthritis; Spondyloarthritis; Tofacitinib; Treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Rheumatol Ther Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google